Q1 26 EPS
$-0.32
MISS 1.72%
Est. $-0.31
Q1 26 Revenue
$0
MISS 100.00%
Est. $578,090
vs S&P Since Q1 26
+28.7%
BEATING MARKET
TNGX +29.6% vs S&P +0.9%
Market Reaction
Did TNGX Beat Earnings? Q1 2026 Results
Tango Therapeutics delivered a disappointing first quarter for fiscal 2026, missing on both the top and bottom lines as the clinical-stage biotech reported zero revenue against a consensus estimate of $578.09 thousand, a 100% year-over-year decline f… Read more Tango Therapeutics delivered a disappointing first quarter for fiscal 2026, missing on both the top and bottom lines as the clinical-stage biotech reported zero revenue against a consensus estimate of $578.09 thousand, a 100% year-over-year decline from $5.39 million, with the shortfall tied directly to the full recognition of deferred revenue from its Gilead collaboration in 2025, leaving no remaining balance to draw upon. On the earnings front, the company posted a loss of $0.32 per share, coming in slightly below the $0.31 consensus estimate by 1.72%, as the net loss widened to $45.51 million. Still, analyst sentiment has remained broadly constructive heading into the print, with at least one firm maintaining a bullish stance and raising its price target to $40 on conviction around vopimetostat's combination potential in RAS-mutant cancers. Management noted its $379.80 million cash position is expected to fund operations into 2028, with pivotal data readouts from vopimetostat combination studies and initial TNG456 results in glioblastoma anticipated in 2026.
Key Takeaways
- • Zero collaboration revenue in Q1 2026 due to full recognition of Gilead collaboration deferred revenue in 2025
- • Lower R&D expenses from discontinuation of TNG908 and reduced TNG961 development costs
- • Higher G&A expenses from increased personnel-related costs including share-based compensation
TNGX Forward Guidance & Outlook
The company expects its cash position of approximately $380 million to fund operations into 2028, beyond anticipated key data inflection points. Key upcoming milestones include initial Phase 1/2 data from the vopimetostat + RAS(ON) inhibitor combination trial in 2026, which may inform a path to a pivotal trial in first-line pancreatic cancer. Vopimetostat monotherapy data in lung cancer and initial TNG456 data in glioblastoma are also expected in 2026. A Phase 1/2 combination study of vopimetostat with ERAS-0015 (Erasca) is planned for initiation in the second half of 2026.
TNGX YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
TNGX Revenue by Segment
With YoY comparisons, source: SEC Filings
“We continue to work diligently to advance vopimetostat towards pivotal development in pancreatic cancer and remain highly encouraged by the potential of the ongoing study of vopimetostat in combination with RAS(ON) inhibitors.”
— Malte Peters, Q1 2026 Earnings Press Release
TNGX Earnings Trends
TNGX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TNGX EPS Trend
Earnings per share: estimate vs actual
TNGX Revenue Trend
Quarterly revenue: estimate vs actual
TNGX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.31 | $-0.32 | -1.72% | $0 | -100.00% |
| Q4 25 BEAT FY | $-0.33 | $-0.29 | +11.83% | $0 | -100.00% |
| FY Full Year | $-0.90 | $-0.87 | +3.10% | $62.4M | -0.81% |
| Q3 25 BEAT | $-0.07 | $0.13 | +287.32% | $53.8M | +30.47% |
| Q2 25 MISS | $-0.34 | $-0.35 | -1.92% | $3.2M | -52.55% |
| Q1 25 MISS | $-0.35 | $-0.36 | -4.08% | $5.4M | -19.84% |